<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363877">
  <stage>Registered</stage>
  <submitdate>18/03/2013</submitdate>
  <approvaldate>20/03/2013</approvaldate>
  <actrnumber>ACTRN12613000314729</actrnumber>
  <trial_identification>
    <studytitle>Subconjunctival dexamethasone in routine cataract surgery</studytitle>
    <scientifictitle>A study comparing the postoperative outcomes of cataract surgeries with and without the use of subconjunctival dexamethasone</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cataract</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The administration of a single dose (1ml) of subconjunctival dexamethasone (4mg/ml) injection at the end of uncomplicated cataract surgery. We will examine the amount of post-operative intraocular inflammation and macular oedema following surgery for 1 month post-surgery</interventions>
    <comparator>Cataract surgery without the administration of a single dose of subconjunctival dexamethasone.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Post-operative ocular inflammation (using slit-lamp examination)</outcome>
      <timepoint>1 month post-operatively</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Macular oedema (using optical coherence tomography)</outcome>
      <timepoint>1 month post-operatively</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Level of participant comfort during and following cataract surgery (using a questionnaire with a visual analogue scale)</outcome>
      <timepoint>1 day post-operatively</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complications of surgery (determined by clinical examination) e.g. retinal detachment, uveitis, endophthalmitis</outcome>
      <timepoint>1 month post-operatively</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with visually debilitating cataracts requiring surgery</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with a history of other ocular pathologies or other abnormal ocular examinations </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Participants in this study will have routine cataract surgery either with or without subconjunctival dexamethasone injection.  Whether participants receive an injection of dexamethasone or not will be determined by their surgeon. This study will not determine whether participants receive an injection but will look at the outcomes of surgery. </concealment>
    <sequence>Patients will not be randomised</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>240</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred - Prahran </hospital>
    <postcode>3181 - Prahran</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Alfred </primarysponsorname>
    <primarysponsoraddress>PO Box 315
Prahran VIC 3181</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Alfred Hospital</fundingname>
      <fundingaddress>PO Box 315
Prahran VIC 3181</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>For many years, some eye surgeons have given patients having cataract surgery an injection of dexamethasone (a type of cortisone or steroid) into the surface of the eye (subconjunctival) at the end of surgery. Dexamethasone is approved in Australia to treat inflammation of the eye during and following eye surgery. 

Some surgeons believe the injections are not needed because:
1.	The steroid drops are usually enough to help the eye recover
2.	The injection can occasionally hurt 

Others surgeons use the injection because:
1.	It seems to makes patients eyes more comfortable for the first few days after surgery
2.	It may help vision to improve faster after surgery by reducing the risk of macular oedema (swelling of the central part of the retina)

This study will not determine whether a patient receives a dexamethasone injection but will look at the outcomes of surgery. From this, we hope to show how useful it is to give a subconjunctival injection of dexamethasone at the time of cataract surgery. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Research and Ethics Committee</ethicname>
      <ethicaddress>PO Box 315
Prahran VIC 3181</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>20/03/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Bob Wang</name>
      <address>The Alfred 
PO Box 315
Prahran VIC 3181</address>
      <phone>+61 3 9076 2000</phone>
      <fax />
      <email>bobzwang@gmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Bob Wang</name>
      <address>The Alfred 
PO Box 315
Prahran VIC 3181</address>
      <phone>+61 3 9076 2000</phone>
      <fax />
      <email>bobzwang@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Bob Wang</name>
      <address>The Alfred 
PO Box 315
Prahran VIC 3181</address>
      <phone>+61 3 9076 2000</phone>
      <fax />
      <email>bobzwang@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>